Characteristics of the first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021

被引:54
作者
Houhamdi, Linda [1 ]
Gautret, Philippe [1 ,2 ]
Van Thuan Hoang [3 ]
Fournier, Pierre-Edouard [1 ,2 ]
Colson, Philippe [1 ,4 ]
Raoult, Didier [1 ,4 ]
机构
[1] IHU Mediterranee Infect, Assistance Publ Hop Marseille AP HM, Dept Microbiol, Marseille, France
[2] Aix Marseille Univ, Inst Rech Dev IDR, VITROME, SSA,AP HM, Marseille, France
[3] Thai Binh Univ Med & Pharm, Thai Binh, Vietnam
[4] Aix Marseille Univ, Inst Rech Dev IDR, MEPHI, AP HM, 19-21 Blvd Jean MOULIN, F-13005 Marseille, France
关键词
coronavirus; COVID-19; death; Delta; hospitalization; infection; Intensive Care Unit; Omicron; SARS-CoV-2; vaccination; variant;
D O I
10.1002/jmv.27613
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One thousand one hundred and nineteen cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant cases have been diagnosed at the Institut Hospitalo-Universitaire Mediterranee Infection, Marseille, France, between November 28, 2021, and December 31, 2021. Among the 825 patients with known vaccination status, 383 (46.4%) were vaccinated, of whom 91.9% had received at least two doses of the vaccine. Interestingly, 26.3% of cases developed SARS-CoV-2 infection within 21 days following the last dose of vaccine suggesting possible early production of anti-SARS-CoV-2 facilitating antibodies. Twenty-one patients have been hospitalized, one patient required intensive care, and another patient who received a vaccine booster dose died.
引用
收藏
页码:2290 / 2295
页数:6
相关论文
共 17 条
[1]   Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa [J].
Abdullah, F. ;
Myers, J. ;
Basu, D. ;
Tintinger, G. ;
Ueckermann, V ;
Mathebula, M. ;
Ramlall, R. ;
Spoor, S. ;
de Villiers, T. ;
Van der Walt, Z. ;
Cloete, J. ;
Soma-Pillay, P. ;
Rheeder, P. ;
Paruk, F. ;
Engelbrecht, A. ;
Lalloo, V ;
Myburg, M. ;
Kistan, J. ;
van Hougenhouck-Tulleken, W. ;
Boswell, M. T. ;
Gray, G. ;
Welch, R. ;
Blumberg, L. ;
Jassat, W. .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 :38-42
[2]  
Aksamentov I., 2021, J Open Source Softw, V6, P3773, DOI [10.21105/joss.03773, DOI 10.21105/JOSS.03773]
[3]   A perspective on potential antibody-dependent enhancement of SARS-CoV-2 [J].
Arvin, Ann M. ;
Fink, Katja ;
Schmid, Michael A. ;
Cathcart, Andrea ;
Spreafico, Roberto ;
Havenar-Daughton, Colin ;
Lanzavecchia, Antonio ;
Corti, Davide ;
Virgin, Herbert W. .
NATURE, 2020, 584 (7821) :353-363
[4]   Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021 [J].
Brandal, Lin T. ;
MacDonald, Emily ;
Veneti, Lamprini ;
Ravlo, Tine ;
Lange, Heidi ;
Naseer, Umaer ;
Feruglio, Siri ;
Bragstad, Karoline ;
Hungnes, Olav ;
Odeskaug, Liz E. ;
Hagen, Frode ;
Hanch-Hansen, Kristian E. ;
Lind, Andreas ;
Watle, Sara Viksmoen ;
Taxt, Arne M. ;
Johansen, Mia ;
Vold, Line ;
Aavitsland, Preben ;
Nygard, Karin ;
Madslien, Elisabeth H. .
EUROSURVEILLANCE, 2021, 26 (50)
[5]  
Colson P., 2022, FRONT MICROBIOL, DOI [10.1101/2021.09.10.21262922, DOI 10.1101/2021.09.10.21262922]
[6]   Data, disease and diplomacy: GISAID's innovative contribution to global health [J].
Elbe, Stefan ;
Buckland-Merrett, Gemma .
GLOBAL CHALLENGES, 2017, 1 (01) :33-46
[7]  
Espenhain L, 2021, EUROSURVEILLANCE, V26, DOI [10.2807/1560-7917.ES.2021.26.50.21011462015, 10.2807/1560-7917.ES.2021.26.50.2101146]
[8]   The puzzling mutational landscape of the SARS-2-variant Omicron [J].
Fantini, Jacques ;
Yahi, Nouara ;
Colson, Philippe ;
Chahinian, Henri ;
La Scola, Bernard ;
Raoult, Didier .
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) :2019-2025
[9]  
GARRISON E, 2012, GENOMICS, V1207, P3907, DOI DOI 10.48550/ARXIV.1207.3907
[10]   Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies [J].
Lee, Wen Shi ;
Wheatley, Adam K. ;
Kent, Stephen J. ;
DeKosky, Brandon J. .
NATURE MICROBIOLOGY, 2020, 5 (10) :1185-1191